compare glp 1 agonists Comparison of adverse effects between GLP-1 receptor Comparative features of glucagon-like peptide

7 In patients who meet these criteria, the ADA preferably recommends use of a GLP-1 RA with proven cardiovascular benefit or an SGLT-2 inhibitor with proven cardiovascular benefit provided they have adequate kidney function

2,6 The Australian evidence-based clinical guidelines for diabetes recommend GLP-1RAs as an add-on therapy in patients with cardiovascular disease, multiple cardiovascular risk factors or kidney disease, and intolerance or a contraindication to sodium-glucose cotransporter 2 (SGLT-2) inhibitors

doi: 10.1136/svn-2018-000196 42 DoughertyJAGuirguisEThornbyKA

These injectable therapies are recommended by the American Diabetes Association to lower the chances of heart attack and stroke in patients with diabetes

Nat Rev Mol Cell Biol